Investing.com -- enGene Therapeutics was downgraded by five Wall Street firms after updated interim data from its pivotal LEGEND study of detalimogene in BCG-unresponsive high-risk non-muscle invasive ...

The UK-led OpenBind initiative has reached a major milestone with the release of its first publicly available dataset and ...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

Half of all people using mobile devices for business transfer “sensitive” data over smartphones and tablets, according to a Harris Poll released Thursday. Results of the survey, compiled from the ...

Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned ...

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

If you’re looking for unlimited tablet data, Straight Talk and Total Wireless may be your very best option. Plans are just $10 to $20 a month for those with an existing phone plan from either provider ...